JP2018521020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521020A5 JP2018521020A5 JP2017563311A JP2017563311A JP2018521020A5 JP 2018521020 A5 JP2018521020 A5 JP 2018521020A5 JP 2017563311 A JP2017563311 A JP 2017563311A JP 2017563311 A JP2017563311 A JP 2017563311A JP 2018521020 A5 JP2018521020 A5 JP 2018521020A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- following formula
- pharmaceutically acceptable
- acceptable salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 2
- MNEOHCYSHVKLIC-UHFFFAOYSA-N OC(CC(CC1)CCN1C(c(c(Cl)c1C[n](cc2)c3c2cc(C(F)(F)F)cc3Cl)ccc1Cl)=O)=O Chemical compound OC(CC(CC1)CCN1C(c(c(Cl)c1C[n](cc2)c3c2cc(C(F)(F)F)cc3Cl)ccc1Cl)=O)=O MNEOHCYSHVKLIC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2015/001693 | 2015-06-09 | ||
| PCT/IB2015/001693 WO2016198908A1 (en) | 2015-06-09 | 2015-06-09 | Ror nuclear receptor modulators |
| US201562257806P | 2015-11-20 | 2015-11-20 | |
| US62/257,806 | 2015-11-20 | ||
| US201662343905P | 2016-06-01 | 2016-06-01 | |
| US62/343,905 | 2016-06-01 | ||
| PCT/US2016/036283 WO2016200851A1 (en) | 2015-06-09 | 2016-06-08 | Nuclear receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019118167A Division JP2019178159A (ja) | 2015-06-09 | 2019-06-26 | 核内受容体調節剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521020A JP2018521020A (ja) | 2018-08-02 |
| JP2018521020A5 true JP2018521020A5 (enExample) | 2019-02-28 |
| JP6549735B2 JP6549735B2 (ja) | 2019-07-24 |
Family
ID=56194583
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563311A Expired - Fee Related JP6549735B2 (ja) | 2015-06-09 | 2016-06-08 | 核内受容体調節剤 |
| JP2019118167A Ceased JP2019178159A (ja) | 2015-06-09 | 2019-06-26 | 核内受容体調節剤 |
| JP2020135558A Expired - Fee Related JP6938737B2 (ja) | 2015-06-09 | 2020-08-11 | 核内受容体調節剤 |
| JP2021140781A Active JP7235816B2 (ja) | 2015-06-09 | 2021-08-31 | 核内受容体調節剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019118167A Ceased JP2019178159A (ja) | 2015-06-09 | 2019-06-26 | 核内受容体調節剤 |
| JP2020135558A Expired - Fee Related JP6938737B2 (ja) | 2015-06-09 | 2020-08-11 | 核内受容体調節剤 |
| JP2021140781A Active JP7235816B2 (ja) | 2015-06-09 | 2021-08-31 | 核内受容体調節剤 |
Country Status (36)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170566A (es) | 2015-06-09 | 2018-03-20 | Bayer Pharma AG | Moduladores alostéricos positivos del receptor muscarínico m2 |
| HUE047988T2 (hu) * | 2015-06-09 | 2020-05-28 | Abbvie Inc | Nukleáris receptor modulátorok (ROR) gyulladásos és autoimmun betegségek kezelésére |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| CN109689654A (zh) | 2016-07-11 | 2019-04-26 | 拜耳医药股份有限公司 | 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途 |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| CN108689942B (zh) * | 2017-04-11 | 2023-06-09 | 广东东阳光药业有限公司 | 含氮双环化合物及其制备方法和用途 |
| US11427596B2 (en) * | 2019-07-19 | 2022-08-30 | Indian Institute of Technology Indore | Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications |
| CN110407863B (zh) * | 2019-08-24 | 2021-08-17 | 中国科学院兰州化学物理研究所 | 一种通过转移硼化反应合成烯基硼酸酯类化合物的方法 |
| CN110483561B (zh) * | 2019-08-24 | 2021-07-23 | 中国科学院兰州化学物理研究所 | 一种烯基硼酸酯类化合物的合成方法 |
| CN114436833B (zh) * | 2021-12-27 | 2024-12-24 | 南京红太阳医药研究院有限公司 | 一种替米沙坦关键中间体4′-溴甲基联苯-2-羧酸酯的制备方法 |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
| AU2024267864A1 (en) * | 2023-05-09 | 2025-11-06 | 11949098 Canada Inc. | Inverse agonists of rar related orphan receptors (rors) |
| WO2024254218A2 (en) * | 2023-06-05 | 2024-12-12 | The Board Of Regents Of The University Of Texas System | Non-peptide small molecule fgf14:nav1.6 channel complex protein-protein interaction modulators |
| CN117263810B (zh) * | 2023-09-19 | 2026-01-27 | 上海凌凯科技股份有限公司 | 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法 |
| CN119241538A (zh) * | 2024-09-30 | 2025-01-03 | 陕西科技大学 | 一类三唑并吡啶结构的化合物、合成方法及其应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992004321A1 (en) | 1990-09-10 | 1992-03-19 | Rhone-Poulenc Rorer International (Holdings) Inc. | Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity |
| US5290798A (en) | 1991-09-30 | 1994-03-01 | Merck Frosst Canada, Inc. | (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
| ZA928276B (en) | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
| JP3457694B2 (ja) | 1993-02-04 | 2003-10-20 | 第一製薬株式会社 | インフルエンザ感染予防・治療薬 |
| US5589482A (en) | 1994-12-14 | 1996-12-31 | Pfizer Inc. | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia |
| US6124463A (en) | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
| ATE524441T1 (de) | 2000-12-28 | 2011-09-15 | Daiichi Seiyaku Co | Vla-4-inhibitoren |
| US20070129334A1 (en) | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
| WO2003091211A1 (en) | 2002-03-28 | 2003-11-06 | Sumitomo Pharmaceuticals Co., Ltd. | Novel heteroaryl compounds |
| AU2003297431A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| JP2006525366A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 複素環式カルボン酸置換基 |
| PT1660491E (pt) | 2003-07-28 | 2008-10-10 | Janssen Pharmaceutica Nv | Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h |
| UY28526A1 (es) | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| JP2008504266A (ja) | 2004-06-24 | 2008-02-14 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物及び方法 |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| ES2318577T3 (es) | 2004-10-29 | 2009-05-01 | Eli Lilly And Company | Derivados de cicloalquil lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1'. |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| FR2890071B1 (fr) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| JP2009530274A (ja) | 2006-03-15 | 2009-08-27 | ワイス | ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物 |
| US8026257B2 (en) | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| WO2009063244A1 (en) * | 2007-11-15 | 2009-05-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Pyridazinone derivatives as parp inhibitors |
| US8450363B2 (en) | 2009-02-06 | 2013-05-28 | Elan Pharmaceuticals, Inc. | Inhibitors of Jun N-terminal kinase |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| EP2477963A4 (en) | 2009-09-18 | 2013-02-27 | Zalicus Pharmaceuticals Ltd | ARYLSULFON DERIVATIVES AS CALCIUM CHANNEL BLOCKERS |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US8466186B2 (en) * | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| AU2012287338A1 (en) | 2011-07-25 | 2014-02-27 | Allergan, Inc. | N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| RU2014120166A (ru) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина |
| EP2647628A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Substituted tricyclic compounds with activity towards ep1 receptors |
| WO2014026328A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof |
| WO2014179564A1 (en) | 2013-05-01 | 2014-11-06 | Vitae Pharmaceuticals, Inc. | Thiazalopyrrolidine inhibitors of ror-gamma |
| GEP20186876B (en) * | 2013-08-02 | 2018-07-10 | Pfizer | Heterobicycloaryl rorc2 inhibitors and methods of use thereof |
| US9550771B2 (en) * | 2013-09-11 | 2017-01-24 | Genentech, Inc. | Keto-imidazopyridine derivatives as RORc modulators |
| EP3527569B1 (en) | 2014-02-03 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye |
| TWI675032B (zh) | 2014-10-14 | 2019-10-21 | 美商維它藥物公司 | ＲＯＲ-γ之二氫吡咯并吡啶抑制劑 |
| HUE047988T2 (hu) | 2015-06-09 | 2020-05-28 | Abbvie Inc | Nukleáris receptor modulátorok (ROR) gyulladásos és autoimmun betegségek kezelésére |
-
2016
- 2016-06-08 HU HUE16731721A patent/HUE047988T2/hu unknown
- 2016-06-08 KR KR1020187000451A patent/KR20180014433A/ko not_active Ceased
- 2016-06-08 EP EP19203418.9A patent/EP3636643A1/en not_active Withdrawn
- 2016-06-08 US US15/176,309 patent/US10106501B2/en active Active
- 2016-06-08 MX MX2017015980A patent/MX372543B/es active IP Right Grant
- 2016-06-08 MY MYPI2017704687A patent/MY193715A/en unknown
- 2016-06-08 UA UAA201713051A patent/UA120651C2/uk unknown
- 2016-06-08 RU RU2017146835A patent/RU2715897C2/ru active
- 2016-06-08 WO PCT/US2016/036283 patent/WO2016200851A1/en not_active Ceased
- 2016-06-08 ES ES16731721T patent/ES2774517T3/es active Active
- 2016-06-08 SG SG10201911849SA patent/SG10201911849SA/en unknown
- 2016-06-08 EP EP16731721.3A patent/EP3307734B1/en active Active
- 2016-06-08 CA CA2988502A patent/CA2988502A1/en not_active Abandoned
- 2016-06-08 CN CN201680036750.1A patent/CN107820494B/zh not_active Expired - Fee Related
- 2016-06-08 AU AU2016276316A patent/AU2016276316B2/en not_active Ceased
- 2016-06-08 MA MA051556A patent/MA51556A/fr unknown
- 2016-06-08 RS RS20200097A patent/RS59934B1/sr unknown
- 2016-06-08 UY UY0001036716A patent/UY36716A/es unknown
- 2016-06-08 PT PT167317213T patent/PT3307734T/pt unknown
- 2016-06-08 TW TW105118235A patent/TWI726888B/zh not_active IP Right Cessation
- 2016-06-08 HR HRP20200064TT patent/HRP20200064T1/hr unknown
- 2016-06-08 JP JP2017563311A patent/JP6549735B2/ja not_active Expired - Fee Related
- 2016-06-08 PH PH1/2017/502237A patent/PH12017502237B1/en unknown
- 2016-06-08 BR BR112017026452-8A patent/BR112017026452A2/pt active Search and Examination
- 2016-06-08 PL PL16731721T patent/PL3307734T3/pl unknown
- 2016-06-08 CR CR20170594A patent/CR20170594A/es unknown
- 2016-06-08 TW TW110113121A patent/TW202128619A/zh unknown
- 2016-06-08 DK DK16731721.3T patent/DK3307734T3/da active
- 2016-06-08 LT LTEP16731721.3T patent/LT3307734T/lt unknown
- 2016-06-08 PE PE2022000685A patent/PE20230683A1/es unknown
- 2016-06-08 SI SI201630618T patent/SI3307734T1/sl unknown
-
2017
- 2017-12-01 IL IL256043A patent/IL256043B/en active IP Right Grant
- 2017-12-06 CO CONC2017/0012594A patent/CO2017012594A2/es unknown
- 2017-12-06 ZA ZA2017/08285A patent/ZA201708285B/en unknown
- 2017-12-07 MX MX2020003224A patent/MX2020003224A/es unknown
- 2017-12-07 CL CL2017003147A patent/CL2017003147A1/es unknown
- 2017-12-07 DO DO2017000289A patent/DOP2017000289A/es unknown
-
2018
- 2018-01-08 EC ECIEPI20181225A patent/ECSP18001225A/es unknown
- 2018-08-22 US US16/108,230 patent/US20190055196A1/en not_active Abandoned
-
2019
- 2019-06-26 JP JP2019118167A patent/JP2019178159A/ja not_active Ceased
- 2019-10-16 US US16/654,141 patent/US20210130293A1/en not_active Abandoned
-
2020
- 2020-01-21 CY CY20201100043T patent/CY1122495T1/el unknown
- 2020-04-16 AU AU2020202584A patent/AU2020202584A1/en not_active Abandoned
- 2020-05-08 IL IL274537A patent/IL274537A/en unknown
- 2020-08-11 JP JP2020135558A patent/JP6938737B2/ja not_active Expired - Fee Related
-
2021
- 2021-07-23 US US17/443,264 patent/US20230066771A1/en not_active Abandoned
- 2021-08-31 JP JP2021140781A patent/JP7235816B2/ja active Active
- 2021-09-15 AU AU2021232727A patent/AU2021232727A1/en not_active Abandoned